干扰素辅助治疗肝癌随机对照试验的Meta分析  

Adjuvant treatment with interferon for patients with hepatocellular carcinoma:A Meta analysis based on randomized controlled trials

作　　者：马新福[1] 张成武[1] 文英[1] 赵久达[2] 燕速[1] 才保加[1] 缪魏[1] 王晓龙[1] 

机构地区：[1]青海大学医学院附属医院胃肠外科,青海西宁810000 [2]青海大学医学院附属医院肿瘤内科,青海西宁810000

出　　处：《中国肿瘤生物治疗杂志》2012年第1期81-86,共6页Chinese Journal of Cancer Biotherapy

摘　　要：目的:用Meta分析的方法定量评价干扰素辅助治疗肝癌的效果。方法:计算机检索EMbase、PubMed、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库(CNKI)、维普中文科技期刊数据库,收集有关干扰素辅助治疗肝癌的随机对照试验(randomized controlled trial,RCT),两名评价者单独评价纳入研究的方法学质量并提取资料,用Cochrane协作网提供的RevMan5.0软件进行Meta分析。结果:共纳入8篇RCTs,共计836例患者。Meta分析结果显示,肝癌患者接受基础治疗后,干扰素辅助治疗组在复发率方面与安慰剂组相比,差异有统计学意义[RR=0.86,95%CI(0.77,0.96),P<0.05];两组在病死率方面的差异也有统计学意义[RR=0.64,95%CI(0.54,0.76),P<0.05]。结论:干扰素辅助治疗可以降低肝癌患者的病死率和复发率,但远期疗效尚待大样本、高质量的RCTs进一步证实。Objective： To quantitatively assess the efficacy of interferon（IFN） in the adjuvant treatment for patients with hepatocellular carcinoma（HCC） using Meta analysis.Methods： Randomized controlled trials（RCTs） of adjuvant treatment with interferon for patients with HCC were searched in Embase,Medline,Cochrane Library,Chinese biomedicine literature database,Chinese Scientific Journals full-text database,and Chinese Journal full-text databases.Two reviewers independently assessed the quality of included studies and extracted data.Meta analysis was carried out using Review Manager（version 5.0） provided by Cochrane Collaboration.Results： Eight RCTs totaling 836 patients were included.Meta analysis showed that the adjuvant treatment with IFN significantly reduced the recurrence rate after curative treatment of HCC,with a pooled risk ratio of 0.86（95 percent confidence interval 0.77 to 0.96）;the effect on reduction in mortality rate was still significant with a pooled risk ratio of 0.64（95 percent confidence interval 0.54 to 0.76）.Conclusion： IFN has a beneficial effect on both mortality rate and tumour recurrence,and the results still need to be confirmed by RCTs of high quality and large sample size.

关 键 词：干扰素 肝癌 辅助治疗 随机对照试验 META分析 

分 类 号：R735.7[医药卫生—肿瘤] R730.54[医药卫生—临床医学]